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AbStRAct
Infection by Herpes Simplex Virus (HSV) type I and II cause a worldwide medical problems. HSV-I infections 
are common in oral and perioral area. After primary infection, HSV becomes latent in the dorsal root ganglia and 
recurrences are caused by many stimuli. Antiviral agents, prevention of transmission, suppression of recurrences 
are current management of HSV infection. Objective: to discuss the management of Recurrent Intraoral Herpes 
(RIH) infection. case report: a 21 years old female patient came to hospital with irregular painful ulcers in her 
mouth preceded by prodrome, followed with eruption and outbreak of vesicles. The first laboratory examination 
confirmed high titer of reactive Immunoglobulin M (IgM) and IgG of anti HSV-I and HSV-II. She was diagnosed 
to have RIH and treated with oral Acyclovir, multivitamins, immune stimulant and 0.2% chlorhexidine gargle 
with good healing. Oral Valacyclovir was given after she had another recurrence, with the result of low episodes 
of RIH and continuous titer improvement of reactive IgM and IgG of anti HSV-I and HSV-II. conclusion: Oral 
administration of Valacyclovir as a the oral prodrugs of Acyclovir is effective prophylactic and therapeutic option 
with many advantages against HSV infection.
AbStRAk
Penatalaksanaan infeksi Herpes berulang dengan valacyclovir. Infeksi Herpes Simplex Virus (HSV) tipe 
I dan II mengakibatkan masalah kesehatan di seluruh dunia. Infeksi HSV-I sering mengenai daerah oral dan 
perioral. Setelah infeksi primer, HSV menjadi laten di ganglion dorsal dan kambuh yang dipicu oleh berbagai 
stimuli. Penatalaksanaan infeksi HSV adalah pemberian obat antivirus, pencegahan transimisi, penurunan tingkat 
kekambuhan. tujuan: membahas penatalaksanaan infeksi Herpes intraoral berulang. Laporan kasus: pasien 
perempuan 21 tahun datang ke rumah sakit dengan ulser ireguler yang sakit di rongga mulut dan didahului oleh 
gejala prodormal, timbulnya vesikel yang kemudian pecah. Hasil pemeriksaan laboratorium menunjukan titer 
Imunoglobulin (Ig) M dan IgG anti HSV-I dan II yang reaktif. Acyclovir, multivitamin, stimulus imun, obat 
kumur klorheksidin 0,2% diberikan dan pasien sembuh. Valacyclovir oral diberikan setelah pasien mengalami 
kekambuhan dengan hasil penurunan tingkat rekurensi dan perbaikan titer reaktif IgM dan IgG anti HSV-I dan 
II. Simpulan: valacyclovir oral sebagai obat prodrug Acyclovir yang efektif dalam terapi dan profilaksis dengan 
berbagai keuntungan dalam mengobati infeksi HSV.
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INtRODUctION
The Herpes Simplex Viruses type I (HSV-I) and type 
II (HSV-II) belong to the α – Herpesviridae and cause 
a wide variety of clinical disorders.1-6 HSV infections 
on humans are depending on the antigenic type of the 
virus, site of inoculation and response of host immune.7 
Recurrent intraoral herpes (RIH) infection is less 
common in an immunocompetent host than Recurrent 
Herpes Labialis (RHL). HSV-II infection is the most 
prevalent cause of genital ulcerations of sexual nature 
worldwide.1 The prevalence of HSV-I infection is 45% 
to 98% of the world population and increases from 
childhood to adulthood (70-80%) with seroprevalence 
higher in lower socioeconomic groups. The HSV-II 
seroprevalence has increased with 20% to 25% of US 
adult have positive for HSV-II antibodies by the age 
of 40.1,5 
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Pr imar y HSV-I  (90% of  cases)  and HSV-I I 
(occasionally) infection in human oral site is known 
as primary herpetic gingivostomatitis and transmitted 
by direct contact of mucous membranes or abraded 
skin to the lesions or mucosal secretions of an active 
primary or recurrent infection.1,8 HSV invades 
epithelial cells and replicate intracellular at site of 
primary exposure.1 
After primary infection, HSV ascends through the 
periaxonal sheath of sensory nerves to the trigeminal, 
cervical, lumbosacral or autonomic ganglia of the 
host nervous system.1,6 Virus replicates and exists in 
an immunologically shielded state until reactivation 
is triggered spontaneously sometimes periodically 
by different stimuli e.g exposure to ultraviolet 
light, mechanical trauma, cosmetic disfigurement, 
psychological distress, fever, dietary factors and 
immunosuppression.1,3,5
Current management of HSV infection is to prevent 
transmission, suppress of recurrance, attenuate 
of clinical course, viral shedding complications, 
palliation,avoidance of trigger factors and promotion 
of healing. Antiviral agents ec Acyclovir and 
Valacyclovir have been used in the treatment of HSV 
infections.1-6 
In this case report, we discuss the management of a 
21 years old immunocompetence female patient with 
RIH who has frequent recurrent episodes. She was 
treated with systemic Acyclovir, immune supplement 
and then Acyclovir was replaced with Valacyclovir 
and instruction to prevent transmission.
cASE REPORt
Female patient, 21 years old came to the Oral Medicine 
Clinic RSCM with chief complaint of painful ulcers 
in her mouth since 3 days ago. Previously, she had 
prodrome symptoms followed by vesicles eruption 
on labial, buccal mucosa, lateral and dorsum of 
the tongue then ruptured in 1-2 days after forming 
irregular pattern (Figure 1). Tenderness and swelling 
of submandibular and servical lymph nodes were 
documented. The patient always has a recurrent 
oral ulcers before menstruation and often get cough, 
flu, sleep disturbance. Previously in 2010, she had 
Herpes infection according to the dermatologist. 
The immunology examination of serum specimen 
confirmed seropositive 2.46x increase in titer of 
Immunoglobulin M (IgM) of anti HSV-I and 7.03x 
titer of Immunoglobulin G (IgG) of anti HSV-I, 1.02x 
titer of IgM of anti HSV-II and 1.72x titer of IgG of anti 
HSV-II (normal range titer : <0.9). The haematology 
examination showed low count of Hemoglobin (Hb) 
and Eritrocyte Sedimentation Rate (ESR). She was 
diagnosed to have RIH infection.
Acyclovir 200mg 5 t imes a day for 10 days, 
multivitamins, and 0.2% Chlorhexidine were given and 
after 10 days, the ulcers were healed. We instructed the 
patient to avoid sun exposure and use sunscreen. Two 
months later, new vesicles were found on palatal, labial 
mucosa, dorsum and lateral of the tongue. The patient’s 
obedience to accomplish Acyclovir 5 times a day was 
poor. Acyclovir was substituded with Valacyclovir 
500mg twice a day for 15 days with the result no new 
vesicles were erupted and the ulcers were healed. 
Unfortunately the patient’s condition was exhausted 
with sleep disturbance and new vesicles were found 
on labial mucosa, dorsum and ventral and apex of the 
tongue although the patient continued with Acyclovir 
200 mg 5 times a day after Valacyclovir was run out. 
She still consumed immune supplement 3 times a 
day. The recurrence of HSV infection on lateral of 
the tongue need to be treated again with Valacyclovir 
500mg 3 times a day for two weeks with the result of no 
new vesicles and ulcers. Episodes of recurrent of HSV 
infection were decreased into 1 episode per month and 
Acyclovir 200mg 3 times a day for 28 days was given 
as prophylaxis treatment. 
We performed Polymerase Chain Reaction (PCR) to 
detect DNA of HSV on an lower labial mucosa ulcer 
by swabbing vigorously using sterile cotton swab and 
immediately sent the sample to the Departement of 
Microbiology FKUI/RSCM using freezed container. 
The result of PCR was negative with no finding of 
DNA band of HSV. The immunology examination 
of serum specimen confirmed seropositive 5.75x 
increase in titer of IgM of anti HSV-I, 1.99x IgG 
of anti HSV-I, 0.44x IgM of anti HSV-II, 0.94x 
IgG of anti HSV-II (normal range titer: <0.9). 
The haematology examination showed low count 
of hematocrit (Ht), neutrophils and increased of 
Erythrocyte Sedimentation Rate (ESR), monocyte, 
blood creatinine. 
Because of low patient’s obedience and suspected 
clinical resistance of Acyclovir, the medication was 
substituted with Valacyclovir 500mg twice daily 
for one month as prophylactic therapy for HSV 
infection with under supervision for any side effects 
of Valacyclovir. After a month of Valacyclovir, the 
immunology examination confirmed seropositive 
2.74x increase in titer of IgM of anti HSV-I, 4.65x 
IgG of anti HSV-I, 0.66x IgM of anti HSV-II, 
0.93x IgG of anti HSV-II (normal range titer :<0.9). 
The haematology examination showed low count 
of Hematocrit (Ht), neutrophils and increased of 
Eritrocyte Sedimentation Rate (ESR), while the 
screening test for HIV antibody was negative, CD4 
count was 753cells/µL (normal range 410 – 1590), 
CD8 count was 683cells/µL (normal range 190-1140). 
Figure 2.
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Figure 1. Painful multiple irreguler ulcers surrounded by erythematous area on various areas of oral mucosa. (A-E)
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Figure 2. Ulcerated oral mucosa healed after treatment with two weeks of 500mg Valacyclovir (A-D).
A
C
B
D
DIScUSSION
Recurrence of HSV infection is a reactivation of HSV 
lead to asymptomatic viral shedding; recrudescence 
is a viral reactivation with clinical manifestations. 
Recurrence is triggered by internal and external trigger 
and leading to proliferative state.1,3 In our patient, 
we suggest that physchological stress, fatigue and 
menstruation as triggering factors of recrudescence of 
HSV inffection. Infection in the mouth is less common 
than herpes labialis and unusual in otherwise healthy 
persons.4
The seropositive of IgM and IgG antibodies to HSV-I 
and HSV-II in our patient can be a marker of HSV-II 
induced recurrent orofacial disease although it is rare.1 
Although presence of IgG doesn’t indicate reinfection, 
recurrent infection or immunity. Immunoglobulin M 
can be demonstrated for weeks after primary infection.9 
Reactivation are less frequent after the age of 35 and 
contrary more frequent before the age of 35 as it happens 
in our patient. Recurrent episodes are milder and shorter 
in duration with minimal systemic involvement. Oedem 
on upper lips in our patient known as RHL which 
typically affects the outer vermilion border and adjacent 
cutaneous region. Recurrent Intraoral Herpes typically 
located on tongue and keratinezed mucosa of the hard 
palate and attached gingiva.1
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Realtime amplification techniques (PCR) is a high 
specifity and sensitivity test which can detect small 
piece of DNA of the virus and low levels of HSV 
shedding. Because of the rapid development of the 
vesicle stage (<12 h) and the fast decrease in detectable 
virus after 48 h may be the reasons why the result is 
negative although viral shedding still continues for 
3 to 8 days after the lesions have resolved.1,3,9 Many 
antivirus drugs have been used to overcome and 
inhibit the viral DNA synthesis. It can be achieved by 
a variety of process: direct inhibition of the viral DNA 
polymerase by competition with the natural nucleoside 
triphosphate (dGTP in the case of the triphosphate 
of Acyclovir, ganciclovir and penciclovir), chain 
termination of the growing viral DNA (acyclovir) 
or DNA strand breakage after incorporation of the 
unnatural nucleotide in the viral DNA.1-4
Acyclovir {9-[(2-hydroxyethoxy)methyl)guanine]} 
is a nucleoside analogue of guanosine and by 
phosphorylation transformed its active state by viral 
thymidine kinase (TK). The affinity of Acyclovir for 
herpesvirus encoded TK is approximately 200 times 
greater than for human TK, thus phosphorylation of 
Acyclovir by the human enzyme occurs at a negligible 
rate. This selective affinity results in the activation 
and concentration of Acyclovir in virus-infected 
cells.4 Following phosphorylation to Acyclovir 
monophosphate (aciclo-GMP), normal host cellular 
enzymes catalyse the sequential phosphorylation to 
Acyclovir diphosphate (aciclo-GDP) and Acyclovir 
triphosphate (aciclo-GTP); this nucleoside triphosphate 
is a potent inhibitor of viral DNA synthesis as it 
competes with viral nucleotides for incorporation into 
viral DNA. Once incorporated, it terminates DNA 
chain synthesis (and thus inhibits viral replication), 
giving rise to nonfunctional DNA strands.4 
The antiviral activity of Acyclovir may be effective in 
reducing the duration of symptoms of recurrent HSV-1 
infection, although the optimal timing and dose of the 
treatment are uncertain. Intravenous Acyclovir will 
still the first line for the management of severe cases 
which require hospitalization such as neonatal herpes, 
HSV encephalitis or disseminated HSV infections in 
immunocompromised hosts 3,4
The prophylactic oral Acyclovir with adjustment to 
the many situations can reduce the frequency and 
severity of recurrent attack of herpetic infection in 
immunocompromised patients, although the dose, 
optimal timing and duration of treatment is uncertain 
and can vary in different situations.4 Titer of IgM, IgG 
of anti HSV-I and HSV-II from the 1st and 2nd result 
showed decreased titer count because of the use of 
Acyclovir prophylactic therapy for 1 month.9
Herpes simplex virus type 1 infection in immunocom-
petent patients usually requires short-term antiviral 
therapy, thus HSV drug resistance is unlikely to arise 
(less than 3%) and the incidence of resistant HSV-
I strains remains low (0.5% in immunocompetent 
patients).2,5 We suspected our patient had clinically 
resistant HSV to Acyclovir because Acyclovir did not 
reduce the vesicles formation, severity and duration of 
the symptoms. These may be caused by one or more 
of the following mechanisms: complete deficiency in 
viral TK activity, decreased production of viral TK 
(TK low producer virus), viral TK protein with altered 
substrate specificity (Tk altered virus; the enzyme is 
able to phosphorylate thymidine not Acyclovir), or a 
viral DNA polymerase with altered substrate specific-
ity (DNA pol altered). A TK-deficient phenotype has 
been observed in 95% of Acyclovir-resistant isolates. 
However, several reports have demonstrated that at 
least some TK activity is needed for HSV reactivation 
from latency in neural ganglia.4
Valacyclovir is the L-valine ester prodrug of Acyclovir 
and has the same mechanism of action, requiring Tk 
dependent conversion to the monophosphate form. 
Valacyclovir is absorbed from the gastrointestinal 
tract and converted to Acyclovir by intestinal and 
hepatic first pass metabolism. Sixty-three percent of 
the Valacyclovir oral dose is absorbed and converted 
to Acyclovir, compared with the 15–21% absorption of 
orally administered Acyclovir. Acyclovir is detected 
in plasma 15 min after Valacyclovir administration. 
Thus, Valacyclovir is increasing the limited oral 
bioavailability of Acyclovir three to f ive-fold. 
Valacyclovir has a safety profile similar to Acyclovir, 
with mild neurotoxicity and severe nephrotoxicity in 
animals at single doses of 1 and 2–5g/kg) respectively.4
Nowadays, systemic Valacyclovir is effective for the 
treatment of herpes labialis especially when started 
during the prodrome of the disease eventhough the 
optimal dose is still unkown. It has more convenient 
dosing regimen (once, twice or three times daily 
compared with five times daily for Acyclovir) and it is 
likely that Valacyclovir will finally replace Acyclovir 
in the oral treatment of HSV or VZV infections in 
immunocompetent persons.7 For these advantages, we 
choose Valacyclovir for the prophylactic therapy of 
recurrent HSV infection with supportive treatment such 
as immune supplement, topical 0.2% chlorhexidine. 
Chlorhexidine digluconate is effective against gram-
positive organisms, gram-negative organisms, aerobes, 
facultative anaerobes, and yeast.11 We also gave 
instruction to take good rest,avoid sun exposure and 
prevent cross infection by avoid kissing anyone, share 
kitchen or bathroom utensils.3 
The adverse events and drug-related adverse events 
of Acyclovir and Valacyclovir are headache, nausea, 
diarrhoea, nephrotoxicityand a small number of cases 
of rash, hallucinations, confusion, dyspepsia, dry mouth 
and flatulence.4 It is important to follow up the patient’s 
condition when long term or prophylactic therapy with 
the laboratory examination of kidney and liver function. 
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cONcLUSION
Current therapeutic modalities include preventive 
measures, non specific immune stimulation, topical 
applications of antiseptic, antiviral agents. Oral 
administration of VCV as a the oral prodrug of ACV 
is effective prophylactic and therapeutic option with 
many advantages against HSV infection and nowadays 
is replacing ACV. 
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